


Amendments to the Claims

1. (Currently Amended) A benzisothiazole-3(2H)-one compound of formula (I)



(I)

wherein;

R₁ is the group ~~(C₅-C₇)alkyl, (C₄-C₁₂)haloalkyl, -CF₃, allyl, (C₄-C₁₂)alkenyl, (C₄-C₁₂)alkynyl, (C₁-C₈)alkylcycloalkyl, (C₃-C₈)cycloalkyl, substituted benzyl, (C₁-C₁₂)alkylheterocyclic radical, (C₃-C₄), and (C₂-C₄)alkylaryl, or aryl~~ wherein the aryl or heterocyclic group is optionally substituted and the benzyl is substituted with 1 to 3 groups independently selected from (C₁-C₁₂)alkyl, (C₂-C₁₂)alkenyl, (C₁-C₁₂)alkoxy, (C₁-C₂)alkylcycloalkyl, and (C₁-C₁₂)haloalkyl;

R₂ is hydrogen;

R₃, R₄, R₅, and R₆, are each independently selected from hydrogen, ~~(C₁-C₄)alkyl, (C₂-C₄)alkenyl, -O-(C₁-C₃ alkyl), COOH, C(O)(C₁-C₃ alkyl), C(O)O(C₁-C₃ alkyl), -CF₃, and halo~~ (C₂-C₁₂)alkyl, (C₄-C₁₂)haloalkyl, (C₄-C₁₂)alkoxyalkyl, (C₄-C₁₀)thioalkyl, hydroxy, (C₂-C₁₂)alkenyl, (C₂-C₁₂)alkynyl, (C₄-C₁₂)alkylaryl, (C₄-C₁₂)alkylcycloalkyl, (C₄-C₁₂)alkylheterocyclic, C(O)C₄-C₆alkyl, C(O)OC₄-C₆alkyl, phenyl or aryl; wherein each of alkyl, alkenyl, phenyl or aryl groups may be optionally substituted with one to three substituents selected from halo, amino, halo, C₁-C₆alkyl, (C₂-C₆)alkenyl, (C₁-C₆)haloalkyl; or a pharmaceutically acceptable salt, solvate or isomer thereof.

2. (Canceled)


3. (Currently Amended) A compound according to Claim 1 wherein R₁ is ~~allyl(C₅-C₇)alkyl, (C₄-C₆)alkenyl, O-(C₁-C₃alkyl), (C₃-C₄)alkylcycloalkyl, or -CF₃, or~~ aryl.

4. (Currently Amended) A compound according to Claim 1 wherein R₁ is benzyl substituted with 2 substituents selected from (C₁-C₆)alkyl, (C₂-C₄)alkenyl, ~~O-(C₁-C₃alkyl),~~ (C₁-C₄)alkylcycloalkyl, and -CF₃.

5. (Canceled)

6. (Currently Amended) The compound of Claim 1 wherein R₅ is the group represented by ~~COOH, C(O)(C₁-C₃alkyl), C(O)O(C₁-C₃alkyl),~~ chloro, bromo or CF₃.

7. (Currently Amended) ~~A compound of formula (I)~~




~~wherein R₁ through R₆ are selected to provide a compound selected from the group consisting of:~~


- ~~3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid allylamide;~~
- ~~3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid pentylamide;~~
- ~~3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid hexylamide;~~
- ~~3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid (5-methyl-hexyl)-amide;~~
- ~~3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid cyclohexylamide;~~
- ~~3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid 2-methyl-benzylamide;~~
- ~~3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid 3-methyl-benzylamide;~~
- ~~3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid 4-methyl-benzylamide;~~
- ~~3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid 2-ethyl-6-methyl-benzylamide;~~
- ~~3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid 2-isopropyl-6-methyl-benzylamide;~~

3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid phenethylamide;
~~3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid (2-thiophen-2-yl-ethyl)-amide;~~
~~3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid (3-phenyl-propyl)-amide;~~
~~3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid (4-phenyl-butyl)-amide;~~
 3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid (4-cyclohexyl-butyl)-amide;
~~5-Methyl-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid butylamide;~~
~~6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid propylamide;~~
~~6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid isopropylamide;~~
~~6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid butylamide;~~
~~6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid hexylamide;~~
 6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid cyclohexylamide; and


8. (Currently Amended) A benzisothiazole-3(2*H*)-one compound represented by the formulae below(C1), (C2), (C3), or (C4):




(C1),



(C2),




(C3),



9. (Currently Amended) A pharmaceutical formulation comprising a benzisothiazole-3(2H)-one compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent.


10. (Currently Amended) A method of inhibiting hepatic lipase ~~and/or endothelial lipase activity using~~ a therapeutically effective amount of benzisothiazole-3(2H)-one compound of formula I, wherein R₁-R₆ are as defined in claim 1



or a pharmaceutical acceptable salt, ~~solvate, or prodrug~~ thereof.

11. (Canceled).

12. (Currently Amended) A pharmaceutical formulation containing a therapeutically effective amount of the compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein R₁-R₆ are defined as in claim 1



I


formulated for the treatment ~~and/or amelioration~~ of the effect of elevated hepatic lipase ~~and/or~~
~~endothelial lipase~~ activity.

13-15. (Canceled)

16. (Previously Presented) The method of claim 10 wherein the benzisothiazole-3(2H)-one compound is formulated with a with a pharmaceutically acceptable carrier or diluent.

17. (Canceled)

18. (New) A method of treating hypercholesterolemia, hyperlipidemia, or atherosclerosis using a therapeutically effective amount of benzisothiazole-3(2H)-one compound of formula I, wherein R₁-R₆ are as defined in claim 1



I

or a pharmaceutical acceptable salt thereof.